The tiny device developed by Professors John Rogers, Igor Efimov, and Yonggang Huang can be inserted with a syringe, and then dissolve after it’s no longer needed.
In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...
BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...
Intuitive customers are showing increased interest in cardiac surgery, and it's invested in robotic heart surgery startup ...
Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...